The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TELO | -74.56% | N/A | N/A | -77% |
| S&P | +13.95% | +78.35% | +12.25% | +38% |
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Baltimore, MD.
No news articles found for Telomir Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $44.87M | -76.4% |
| Market Cap / Employee | $8.97M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$1,102.29K | 81.6% |
| EBITDA | -$1,146.48K | 80.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.33M | 778.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -266.47% | 457.4% |
| Return On Invested Capital | -673.49% | -632.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$927.26K | 7.5% |
| Operating Free Cash Flow | -$927.27K | 7.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 275.95 | 149.47 | -231.05 | 88.14 | -27.32% |
| Price to Tangible Book Value | 275.95 | 149.50 | -230.92 | 88.14 | -27.32% |
| Enterprise Value to EBITDA | -41.72 | -43.76 | -7.25 | -32.89 | 4.37% |
| Return on Equity | -813.1% | -876.8% | -1575.4% | -303.2% | -82.75% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
